EpimAb Biotherapeutics

About EpimAb Biotherapeutics

EpimAb Biotherapeutics is a privately owned biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform.
Monoclonal antibodies have transformed the treatment of human diseases, including inflammatory and autoimmune diseases, cancer, severe infections and many rare conditions over the course of the past two decades. Bi-specific antibodies are engineered from two different monoclonal antibodies and combine their key features into one molecule.
YEAR FOUNDED:
February 2015
LEADERSHIP:
CEO: Chengbin Wu, Ph.D
CBO: Dr. Stephan Lensky
SCIENCE:
Please click here for EpimAb's technology.